CURRICULUM VITAE - GUILHERME AMORIM

Email: guilhermepessoaamorim@gmail.com

1. WORK EXPERIENCE:

Jan 2019 – present: Clinical Research Fellow, Clinical Trial Service Unit – Oxford Population Health, University of Oxford, UK

Main research projects:

- 1. A Study of Cardiovascular Events in Diabetes (ASCEND)-PLUS (oral semaglutide for primary cardiovascular prevention in diabetes), 2024-present (ISRCTN76193287)
- 2. Randomised Evaluation of COVID-19 Therapy (RECOVERY), 2020-present (NCT04381936)
- 3. Active Monitoring for AtriaL Flbrillation (AMALFI; remote screening for silent atrial fibrillation in primary care), 2019-present (ISRCTN15544176)
- 4. A Randomized Trial Assessing the Effects of Inclisiran on Clinical Outcomes Among People With Cardiovascular Disease (ORION-4), 2019-present (NCT03705234)

Main deliverables:

- Led recruitment of >5,000 participants in the AMALFI trial; contributed to recruitment of >12,000 UK participants in ORION-4 and >49,000 participants in RECOVERY
- Main author of the AMALFI statistical analysis plan
- Led NHS data linkage request submissions and linkage data collection from 27 primary care practices and centralised NHS England datasets (AMALFI and ORION-4)
- Developed data-driven algorithms to identify safety events and medication exposure (RECOVERY, ORION-4, AMALFI)
- Developed and led a centralised pre-screening procedure using linked hospital lab data (ORION-4)
- Led or contributed to 24 research papers (6 as first author), total >19,000 citations (h-index 22), including major contributions to global clinical guidelines on COVID-19 (RECOVERY trial)
- Presented research outputs at several international conferences, including European Society of Cardiology Congress 2017 and 2021

Jan 2019 – present: Honorary/Locum Medical Doctor

Oxford University Hospitals NHS Foundation Trust – Oxford, UK

Roles: admission clerking, ambulatory medical care, ward cover; total >1000 hours

August 2023: External Medical Advisor, Medicines and Healthcare products Regulatory Agency (MHRA), UK Role: assessment of a trial protocol in chronic kidney disease submitted for regulatory approval

2018: General Medical Residency, Gaia-Espinho Hospital Centre, Portugal

2. PROFESSIONAL SKILLS

Clinical research: clinical study design, regulatory/ethics submissions, participant recruitment, safety monitoring and reporting, clinical management, clinical event adjudication, electronic data linkage, statistical analysis, Clinical Data Interchange Standards Consortium (CDISC) standards, scientific writing, grant writing, patient/public engagement, data protection,

Data management, analysis, and visualisation: R (proficient), SQL (intermediate), Python (beginner), Git (beginner)

Real-world data: clinical codelist development (ICD-10, SNOMED-CT), algorithm development using multiple nationwide hospital admissions, laboratory, and medication use datasets (England/Scotland)

Clinical medicine: acute general medicine, cardiovascular disease, diabetes, COVID-19 Language skills: English (proficient), Portuguese (native)

3. OUALIFICATIONS

2024 - present: Postgraduate Diploma in Artificial Intelligence, University of Essex, UK (online)

- 2020 2024: Doctor of Philosophy (DPhil) in Population Health, University of Oxford, UK Project description: validation of 4 nationwide real-world datasets (England/Scotland) on medication use in the community and inpatient setting to identify exposure to study and concomitant medications in large-scale randomised trials in cardiovascular disease and COVID-19, including algorithm and clinical codelist development for >80 drug use phenotypes among >46,000 distinct individuals
- 2011 2017: Master's Degree in Medicine, Faculty of Medicine of the University of Porto Portugal Final mark 16/20, grade B (top 11%); national medical specialty application grade: 93/100 (top 7%)

4. TEACHING AND SUPERVISION

- 2020 present: Guest lecturer and academic supervisor, MSc in Clinical Trials, Oxford Population Health, University of Oxford
 - Role: remote lectures/interviews on conducting clinical trials within primary care, medical device trials, and pilot studies; supervised two MSc students and an Academic Foundation doctor
- 2018: Lecturer, Academia da Especialidade Portugal: large group lecturing to final year medical students

5. HONOURS AND AWARDS

- 2023: Clinical Study Grant British Heart Foundation (lead applicant, ~£290,000)
- 2020: Doctor of Philosophy Scholarship Medical Research Council Population Health Research Unit, University of Oxford (~£142,000)
- 2020: European Society of Cardiology Travel Grant ESC Heart & Stroke Congress
- 2018: Sanofi Cardiology Prize, Portuguese Society of Cardiology best national clinical research project
- 2017: Best Moderated Poster, European Society of Cardiology Congress 2017
- 2012: *"Vicente José de Carvalho"* Award, Faculty of Medicine of the University of Porto best student in Anatomy

6. SELECT COURSES AND TRAINING

Ongoing: High Performance Collaboration: Leadership, Teamwork, and Negotiation, Northwestern University (online)

Ongoing: Exercising Leadership: Foundational Principles, Harvard University (online)

- 2024: Good Clinical Practice training, University of Oxford
- 2019: Statistical Analysis with R for Public Health Specialization, Imperial College London (online)
- 2018: Advanced Course in Clinical Research in Cardiology, Portuguese Society of Cardiology
- 2018: Blended Learning Introduction to Clinical Studies, Faculty of Medicine of the University of Porto Portugal; ECTS credits: 6; final grade: 19/20

7. SELECT PUBLICATIONS

- 2024: Pessoa-Amorim G, Goldacre R, Crichton C, Stevens W, Nunn M, King A, Murray D, Welsh R, Pinches H, Rees A, Morris EJA, Landray MJ, Haynes R, Horby P, Wallendszus K, Peto L, Campbell M, Harper C, Mafham M. <u>Clinical trial results in context: comparison of baseline characteristics and outcomes of 38,510 RECOVERY trial participants versus a reference population of 346,271 people hospitalised with COVID-19 in England. Trials. DOI: 10.1186/s13063-024-08273-9</u>
- 2021: RECOVERY Collaborative Group (joint first-author). <u>Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.</u> The Lancet. DOI: 10.1016/S0140-6736(21)01825-0
- 2021: Pessoa-Amorim G, Campbell M, Fletcher L, Horby P, Landray M, Mafham M, Haynes R. <u>Making trials part of good clinical care: lessons from the RECOVERY trial.</u> Future Healthcare Journal. DOI: 10.7861/fhj.2021-0083
- 2021: Pessoa-Amorim G, Mafham MM. <u>The RECOVERY trial: cardiovascular implications of a large, simple randomized trial in COVID-19.</u> Cardiovascular Research. DOI: 10.1093/cvr/cvab239
- 2021: Spartera M, Stracquadanio A, Pessoa-Amorim G, Von Ende A, Fletcher A, Manley P, Ferreira VM, Hess AT, Hopewell JC, Neubauer S, Wijesurendra RS, Casadei B. <u>The impact of atrial fibrillation and stroke risk factors on left atrial blood flow characteristics</u>. European Heart Journal Cardiovascular Imaging. DOI: 10.1093/ehjci/jeab213
- 2020: Pessoa-Amorim G, Campbell M, Peto L (joint authors): <u>The inside story of Recovery: how the world's largest COVID-19 trial transformed treatment and what it could do for other diseases.</u> The Conversation (https://theconversation.com/the-inside-story-of-recovery-how-the-worlds-largest-covid-19-trial-transformed-treatment-and-what-it-could-do-for-other-diseases-184772)
- 2020: Pessoa-Amorim G, Camm CF, Gajendragadkar P, De Maria GL, Arsac C, Laroche C, Zamorano JL, Weidinger F, Achenbach S, Maggioni AP, Gale CP, Poppas A, Casadei B. <u>Admission of patients with STEMI since the outbreak of the COVID-19 pandemic. A survey by the European Society of Cardiology</u>. European Heart Journal Quality of Care and Clinical Outcomes. DOI: 10.1093/ehjqcco/qcaa046